-
Recent Posts
- Timeless Good Advice? (Action for Happiness)
- The Diversionary Value of Music Playlists for Patients With Dementia in Accident and Emergency Settings (Nurses.co.uk / BBC News)
- More on the Possible Role of Neuroinflammation in Frontotemporal Dementia (Bazian / Brain)
- COVID-19 Infection: Coronavirus in the UK (DHSC / PHE / BBC News / SCIE / NHS England)
- Interventions to Improve Resilience in People Living With Dementia (Frontiers in Medicine)
Archives
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Verubecestat
Early Promising Signs in Verubecestat Human Drug Trial – Since Dashed (NHS Choices / Science Translational Medicine / Translational Neurodegeneration / Biospace Inc)
Summary Early results from a Phase I trial indicate that the BACE1 inhibitor Verubecestat may effectively reduce β-amyloid formation in human patients with Alzheimer’s Disease. This appears to confirm previous trials with rats, monkeys and healthy young human adults. As … Continue reading →
Posted in Animal Studies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Aducanumab, Aducanumab (Biogen), Aβ40, Aβ42, Amyloid, Amyloid Beta, Amyloid Hypothesis, Amyloid Precursor Protein (APP), Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Amyloidopathy, Anti-Amyloid Therapies, APECS Phase 3 Trial (ClinicalTrials.gov Identifier: NCT01953601), Aspartyl Proteases β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1 or β-Secretase), ß-amyloid, BACE1, BACE1 Inhibitors, Behind the Headlines, Beta-Amyloid, Beta-Amyloid Plaques, Biomarkers, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, Cleveland Clinic Foundation, Department of Biostatistics: Merck Research Laboratories, Department of Clinical Research: Merck Research Laboratories, Department of Global Chemistry: Merck Research Laboratories, Department of Neuroscience: Merck Research Laboratories, Department of Pharmacokinetics Pharmacodynamics and Drug Metabolism: Merck Research Laboratories, Department of Safety Assessment: Merck Research Laboratories, Department of Translational Medicine: Merck Research Laboratories, EPOCH Phase 2/3 Trial (ClinicalTrials.gov Identifier: NCT01739348), β-Secretase 1 (BACE1), Lerner Research Institute, Merck Research Laboratories, PAREXEL (Glendale USA), Phase III APECS Study, sAPPβ, Science Translational Medicine, Translational Biomarkers Department: Merck Research Laboratories, Translational Neurodegeneration, United States, USA, Verubecestat, Verubecestat: Reduction of CSF Aβ and sAPPβ in Healthy Adults and AD Patients
|
Leave a comment
